HomeCompareENTEF vs JNJ

ENTEF vs JNJ: Dividend Comparison 2026

ENTEF yields 10000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENTEF wins by $55137509079256512.00M in total portfolio value
10 years
ENTEF
ENTEF
● Live price
10000.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55137509079256512.00M
Annual income
$54,073,795,673,722,890,000,000.00
Full ENTEF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ENTEF vs JNJ

📍 ENTEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENTEFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENTEF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENTEF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENTEF
Annual income on $10K today (after 15% tax)
$850,000.00/yr
After 10yr DRIP, annual income (after tax)
$45,962,726,322,664,450,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ENTEF beats the other by $45,962,726,322,664,450,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENTEF + JNJ for your $10,000?

ENTEF: 50%JNJ: 50%
100% JNJ50/50100% ENTEF
Portfolio after 10yr
$27568754539628256.00M
Annual income
$27,036,897,836,861,443,000,000.00/yr
Blended yield
98.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ENTEF
No analyst data
Altman Z
-17.7
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENTEF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENTEFJNJ
Forward yield10000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$55137509079256512.00M$30.3K
Annual income after 10y$54,073,795,673,722,890,000,000.00$4,689.40
Total dividends collected$55066727460582336.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ENTEF vs JNJ ($10,000, DRIP)

YearENTEF PortfolioENTEF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$1,010,700$1,000,000.00$10,592$272.30+$1.00MENTEF
2$95,539,393$94,457,943.93$11,289$357.73+$95.53MENTEF
3$8,447,007,736$8,344,780,585.66$12,123$472.89+$8447.00MENTEF
4$698,565,746,383$689,527,448,105.17$13,141$629.86+$698565.73MENTEF
5$54,040,711,670,213$53,293,246,321,583.74$14,408$846.81+$54040711.66MENTEF
6$3,910,851,616,519,516$3,853,028,055,032,387.00$16,021$1,151.60+$3910851616.50MENTEF
7$264,781,167,546,477,440$260,596,556,316,801,570.00$18,122$1,588.22+$264781167546.46MENTEF
8$16,772,556,223,821,672,000$16,489,240,374,546,942,000.00$20,930$2,228.20+$16772556223821.65MENTEF
9$994,124,678,068,810,000,000$976,178,042,909,320,800,000.00$24,792$3,191.91+$994124678068810.00MENTEF
10$55,137,509,079,256,515,000,000$54,073,795,673,722,890,000,000.00$30,274$4,689.40+$55137509079256512.00MENTEF

ENTEF vs JNJ: Complete Analysis 2026

ENTEFStock

ESE Entertainment Inc., an entertainment and technology company, focuses on gaming and esports in Europe and internationally. It consists of multiple assets and operators in the gaming and esports industries. The company's capabilities include physical infrastructure, broadcasting, global distribution for gaming and esports-related content, advertising, simulation racing business unit, and a growing esport team franchise, as well as K1CK Esports. It also engages in the infrastructure business that manages fan engagement for OTT and esports; and provision of gaming related infrastructure, technology, and support. In addition, the company offers out-sourced network services; operates telecommunications network; turnkey simulator packages; builds bespoke simulators; and Virtual Pitstop technology for video game developers, racing fans, and gamers to engage in motorsport related esports. It serves video game developers, publishers, and brands. The company was formerly known as Kepler Acquisition Corp. and changed its name to ESE Entertainment Inc. in August 12, 2020. ESE Entertainment Inc. was founded in 2019 and is headquartered in Vancouver, Canada.

Full ENTEF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ENTEF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENTEF vs SCHDENTEF vs JEPIENTEF vs OENTEF vs KOENTEF vs MAINENTEF vs ABBVENTEF vs MRKENTEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.